Navigation Links
U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds

CHANDLER, Ariz., Oct. 30, 2013 /PRNewswire/ -- Vomaris Wound Care, Inc., a regenerative medical device company specializing in microcurrent field generating technologies for the wound care market, announced that in an effort to identify improved options for wound care, a clinical study to investigate Procellera® Wound Dressing on acute wound healing in U.S. Army Rangers has been launched at the U.S. Army 4th Ranger Training Brigade (RTB) in Fort Benning, Georgia.

The $1 million research initiative is funded by a grant from the U.S. Army Medical Materiel Command (USAMMA) and includes collaborators, such as The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and its Diagnostics and Translational Research Center (DTRC).

The randomized two-arm study will involve up to 80 Rangers. The study is designed to evaluate the efficacy of Procellera® versus the current Army methods.  Procellera® is already available to the public and is used in hospitals, as well as available over-the-counter.

"The Army Rangers are some of the most elite members of our Armed Forces, and deserve to be equipped with the very latest in advanced wound care technology for frontline treatment," said Michael P. Nagel, Vomaris President and CEO. "Procellera® will be put to the test in the toughest of conditions. For the past three years, our company has enjoyed a very collaborative effort with the U.S military on testing and performance of our product. We look forward to the results from this critical trial."

Skin injuries, including cuts, blisters and abrasions, are a common occurrence in military populations that are at high risk for developing infectious complications which become duty-limiting and account for training time losses, attrition and medical costs.

"The USAMMA is extremely grateful to the Fort Benning community, participants, physicians, medics, and researchers who have made this important field product evaluation possible," said Greggory J. Housler, a Biomedical Engineer/Product Manager at USAMMA.

Researchers also aim to investigate wound healing on a cellular level through wound cytokine and chemokine analysis, as well as microbial colonization.

"Ultimately, we hope data from this study can help keep future service members healthier in training and on the battlefield," said Nagel. "New technologies that can reduce healing times and improve quality of life could revolutionize wound care, improve military medicine, and possibly increase military readiness on a significant scale."

The study is expected to end in mid-2014. HJF will provide data management, regulatory, and site monitoring support to the study team, and its researchers at the DTRC will provide quantitative analysis on biomarkers and bacteriology. Vomaris will supply product, technical and scientific support regarding the use of Procellera®.

HJF researchers have already presented three abstracts on Procellera®'s antimicrobial efficacy and its use as a next-generation wound care product in the battlefield at the Symposium on Advanced Wound Care in Las Vegas in September.

In addition to this study, research is ongoing at the Complex Wound and Limb Salvage Center at Walter Reed National Military Medical Center to investigate the use of Procellera® compared to standard of care in the treatment of non-healing soft tissue wounds. 

About Vomaris Wound Care, Inc.
Vomaris Wound Care, Inc., based in Chandler, Arizona, is a leading-edge regenerative medical device company specializing in microcurrent field generating technologies for the wound care market. Its product, Procellera®, is the world's first self-contained antimicrobial wound dressing with a matrix of microcell batteries at its surface. Procellera® is a unique device due to its inherent design with microcurrent technology. Procellera® is indicated for over-the-counter (OTC) and professional (Rx) uses, and is also available to the veterinary market.  Randomized clinical trials are in process looking at other possible wound healing benefits for the use of Procellera®.

For more information, visit or call 480.921.4948.

SOURCE Vomaris Wound Care, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
2. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
3. SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
4. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
5. AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
6. Edison initiates coverage of Derma Sciences
7. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
8. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
9. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
10. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
11. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Post Your Comments:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):